Skip to main content

Duke Cancer Institute

DCI Blog
Events
DCI Members
Contact
Give

Cancer Types and Programs

Primary Brain Cancer
Brain and Spine Metastasis
Breast Cancer
Endocrine Neoplasia
Gastrointestinal Cancer
Gynecologic Cancer
Head and Neck Cancer
Hematologic Malignancies and Cellular Therapy
Immunotherapy
Melanoma and Advanced Skin Cancers
Molecular Tumor Board
Oncologic Reconstructive Surgery
Pediatric Cancers
Prostate and Urologic Cancers
Sarcoma
Thoracic Cancer
Thyroid Cancer

Supportive Care

Supportive Care and Survivorship Center

Research

Cancer Registry
Clinical Trials
Research Programs
Shared Resources

Education and Training

Office of Cancer Research Training and Education Coordination

About DCI

DCI Overview
DCI Members
Nursing
Careers
Community Outreach and Engagement
Contact
DCI blog
Events

Get Involved

Giving Opportunities
Benefits and Special Events
Breakthroughs Magazine

Make an Appointment

Blogs

AI-Driven Biomarker Predicts Optimum Length of Treatment for Prostate Cancer

Published

June 01, 2023

Written By

Sarah Avery

Director, Duke Health News Office

Topics

Center for Prostate and Urologic Cancers
Prostate Cancer
Research

Share

Share This Page

Print Page Or Copy Link Url

Copied to clipboard

Related News

Prostate

Collaborative Procedure to Treat Renal Carcinoma with Venous Involvement

January 06, 2026

Clinical Practice Today

Hoimes smiling

Christopher Hoimes, DO

Perioperative PADCEV Plus Pembrolizumab Significantly Improves Survival in Cisplatin-Eligible Muscle-Invasive Bladder Cancer

December 18, 2025

OncoDaily

Related News

Prostate

Collaborative Procedure to Treat Renal Carcinoma with Venous Involvement

January 06, 2026

Clinical Practice Today

Hoimes smiling

Christopher Hoimes, DO

Perioperative PADCEV Plus Pembrolizumab Significantly Improves Survival in Cisplatin-Eligible Muscle-Invasive Bladder Cancer

December 18, 2025

OncoDaily

Website Privacy Policy
Sitemap
Leading with Heart: Serving Humanity
Notice of Nondiscrimination
Notice of Privacy Practices
Terms and Conditions
Accessibility
© DUKE CANCER INSTITUTE 2026

Back to Top